Banner

Serum pigment epithelium derived factor as a new marker in the metabolic syndrome

• 2017
العودة
معلومات البحث
المؤلفون Jehan H Sabry 1, Osama S. El-Shaaer 1, Amr M. El Hammady 2, and Asmaa .A .El Fallah1
الكلمات المفتاحية Not Available
المجلة العلمية Not Available
الناشر Not Available
المجلد Not Available
العدد Not Available
الصفحات Not Available
publication.type International
رابط البحث Not Available
المواد المرفقة Not Available
الملخص
Background: Metabolic syndrome represents a cluster of related metabolic abnormalities, including central obesity, hyperglycemia, hypertension, dyslipidemia, and insulin resistance, with insulin resistance and central obesity in particular recognized as causative factors. Aim of the study: to determine serum level of Serum pigment epithelium derived factor (PEDF) and to examine whether PEDF serum level are associated with metabolic syndrome risk factor. Materials and Methods: The present study was conducted on 90 subjects subdivided into two groups. Patient group included 70 patients with metabolic syndrome attending the outpatient clinic in Benha University Hospital. and control group, this group included 20 apparently healthy individuals, Blood samples were drawn from all subjects to assess serum levels of PEDF, Hs-CRP, lipid profile, F.B.S, creatinine and uric acid. Results: PEDF level was significantly higher in patient group than control group, significant elevation of Hs-CRP ,FBS,TG ,LDL-cholesterol and uric acid in patient group versus control group and significant decrease of HDL-cholesterol in patient group versus control group. Significant positive correlation between PEDF (patient group) and each of the components of Metabolic syndrome as BMI ,WC,LDL-cholesterol and total cholesterol, triglyceride, systolic &diastolic blood pressure and the accumulation of the number of this component collectively. Conclusion: Based on the evidence presented within the study, PEDF correlate significantly with metabolic syndrome and could provide a minimally-invasive mean for early detection and specific treatment of this disorder. Further research is encouraged to determine the efficacy of applying this biomarker for diagnosis of metabolic syndrome.